Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind, Placebo- and Active-Control, Parallel-Arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.

Trial Profile

A Randomized Double-Blind, Placebo- and Active-Control, Parallel-Arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs Oxycodone; Tapentadol
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 May 2011 Results from a pooled analysis (700020566, 700023303 and 700058693) of a subset of patients aged at least 75 years were presented at the 30th Annual Scientific Meeting of the American Pain Society.
    • 02 Sep 2010 Results from a pooled analysis (700020566, 700023303 and 700058693) were reported at the 13th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top